PExA Valuation

Is PEXA B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PEXA B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PEXA B's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PEXA B's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PEXA B?

Key metric: As PEXA B is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PEXA B. This is calculated by dividing PEXA B's market cap by their current revenue.
What is PEXA B's PS Ratio?
PS Ratio24.7x
SalesSEK 795.66k
Market CapSEK 19.68m

Price to Sales Ratio vs Peers

How does PEXA B's PS Ratio compare to its peers?

The above table shows the PS ratio for PEXA B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
LEVBIO Level Bio
0.9xn/aSEK 19.0m
ATANA Attana
2.2xn/aSEK 10.3m
ISAB Inhalation Sciences Sweden
3.8x59.5%SEK 65.8m
AROC AroCell
2x25.9%SEK 101.8m
24.7xn/aSEK 19.7m

Price-To-Sales vs Peers: PEXA B is expensive based on its Price-To-Sales Ratio (24.7x) compared to the peer average (2.2x).


Price to Sales Ratio vs Industry

How does PEXA B's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
PEXA B 24.7xIndustry Avg. 4.2xNo. of Companies9PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PEXA B is expensive based on its Price-To-Sales Ratio (24.7x) compared to the European Life Sciences industry average (4.2x).


Price to Sales Ratio vs Fair Ratio

What is PEXA B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PEXA B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio24.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PEXA B's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies